Experimental HCV Drugs
Experimental HCV Drugs
ACH-1625 HCV Protease Inhibitor Starts Phase 2 Trial
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 08 July 2011 00:00
- Written by Achillion Pharmaceuticals
Achillion Pharmaceuticals recently announced that the first patients have started treatment in a Phase 2 clinical trial of the experimental HCV protease inhibitor ACH-1625 plus pegylated interferon and ribavirin.
HCV Drug TMC649128 Enters Phase 1b
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 28 June 2011 07:38
- Written by Medivir
A new HCV polymerase inhibitor, TMC649128, is now being tested in a Phase 1b trial, the first stage of evaluating safety and efficacy in a large number of patients.
Sitges Meeting Discusses European Access to New Hepatitis C Drugs
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 17 June 2011 07:01
- Written by Sitges Meeting
Community activists, researchers, and regulatory and pharmaceutical representatives met this month in Sitges, Spain, to discuss early and expanded access to direct-acting antiviral agents for hepatitis C, especially for difficult-to-treat patients including those with HIV/HCV coinfection and cirrhosis. 
Vertex Licenses Alios HCV Protease Inhibitors
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 17 June 2011 07:07
- Written by Vertex Pharmaceuticals
Vertex Pharmaceuticals and Alios BioPharma have agreed to collaborate on development of 2 novel nucleotide analog HCV NS5B polymerase inhibitor candidates, now at the preclinical stage.
HCV Protease Inhibitor Danoprevir Promising in Early Trial
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 14 June 2011 07:54
- Written by Liz Highleyman
Experimental HCV protease inhibitor danoprevir (formerly RG7227 and ITMN-191) was safe and showed good antiviral activity at higher doses in a 14-day study of treatment-naive and previously treated genotype 1 chronic hepatitis C patients. 
Web Design and Development by